GlaxoSmithKline Pharmaceuticals Ltd
NSE:GLAXO

Watchlist Manager
GlaxoSmithKline Pharmaceuticals Ltd Logo
GlaxoSmithKline Pharmaceuticals Ltd
NSE:GLAXO
Watchlist
Price: 2 264.6 INR -0.8% Market Closed
Market Cap: 383.6B INR
Have any thoughts about
GlaxoSmithKline Pharmaceuticals Ltd?
Write Note

GlaxoSmithKline Pharmaceuticals Ltd
EPS (Diluted)

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

GlaxoSmithKline Pharmaceuticals Ltd
EPS (Diluted) Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company EPS (Diluted) CAGR 3Y CAGR 5Y CAGR 10Y
GlaxoSmithKline Pharmaceuticals Ltd
NSE:GLAXO
EPS (Diluted)
â‚ą39
CAGR 3-Years
10%
CAGR 5-Years
-5%
CAGR 10-Years
N/A
Dr Reddy's Laboratories Ltd
NSE:DRREDDY
EPS (Diluted)
â‚ą64
CAGR 3-Years
-18%
CAGR 5-Years
-17%
CAGR 10-Years
N/A
Cipla Ltd
NSE:CIPLA
EPS (Diluted)
â‚ą55
CAGR 3-Years
20%
CAGR 5-Years
22%
CAGR 10-Years
15%
Sun Pharmaceutical Industries Ltd
NSE:SUNPHARMA
EPS (Diluted)
â‚ą46
CAGR 3-Years
21%
CAGR 5-Years
21%
CAGR 10-Years
4%
T
Torrent Pharmaceuticals Ltd
NSE:TORNTPHARM
EPS (Diluted)
â‚ą53
CAGR 3-Years
12%
CAGR 5-Years
26%
CAGR 10-Years
8%
M
Mankind Pharma Ltd
NSE:MANKIND
EPS (Diluted)
â‚ą47
CAGR 3-Years
15%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

GlaxoSmithKline Pharmaceuticals Ltd
Glance View

Market Cap
383.6B INR
Industry
Pharmaceuticals

GlaxoSmithKline Pharmaceuticals Ltd., a subsidiary of the global healthcare juggernaut GSK, stands as a pillar in the pharmaceutical industry, with roots deeply entrenched in innovation and a robust pipeline of healthcare products. This company weaves a narrative of relentless pursuit in the creation and distribution of a wide variety of medicines and vaccines, aimed at improving the quality of human life. Operating predominantly in the areas of pharmaceuticals, vaccines, and consumer healthcare, GSK integrates cutting-edge research with strategic collaborations. This enables them to address pressing medical needs, such as respiratory diseases, HIV, infectious diseases, and oncology, amongst others, thereby leveraging their expertise to cater to diverse healthcare demands. The heart of their revenue generation lies in the seamless amalgamation of research acumen and market presence. By investing significantly in research and development, GSK continually introduces groundbreaking therapies and health solutions. The company has adeptly structured its operations to create a strong global presence, which not only involves selling directly to healthcare providers and governments but also innovating its supply chain to maximize reach. Moreover, GSK's astute marketing efforts ensure that their products are not just effective but also attuned to consumer needs. With a focus on sustainable growth and transformative medicines, GSK’s story becomes a testament to how science-driven strategies can forge pathways to a healthier world while simultaneously fueling the company’s economic engine.

GLAXO Intrinsic Value
1 271.59 INR
Overvaluation 44%
Intrinsic Value
Price

See Also

What is GlaxoSmithKline Pharmaceuticals Ltd's EPS (Diluted)?
EPS (Diluted)
39.2 INR

Based on the financial report for Sep 30, 2024, GlaxoSmithKline Pharmaceuticals Ltd's EPS (Diluted) amounts to 39.2 INR.

What is GlaxoSmithKline Pharmaceuticals Ltd's EPS (Diluted) growth rate?
EPS (Diluted) CAGR 5Y
-5%

Over the last year, the EPS (Diluted) growth was 3%. The average annual EPS (Diluted) growth rates for GlaxoSmithKline Pharmaceuticals Ltd have been 10% over the past three years , -5% over the past five years .

Back to Top